Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; International Center for Brain Science, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan.
Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Exp Neurol. 2023 May;363:114379. doi: 10.1016/j.expneurol.2023.114379. Epub 2023 Mar 11.
COVID-19 causes neurological damage, systemic inflammation, and immune cell abnormalities. COVID-19-induced neurological impairment may be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which directly infects cells of the central nervous system (CNS) and exerts toxic effects. Furthermore, SARS-CoV-2 mutations occur constantly, and it is not well understood how the infectivity of the virus to cells of the CNS changes as the virus mutates. Few studies have examined whether the infectivity of cells of CNS - neural stem/progenitor cells (NS/PCs), neurons, astrocytes, and microglia - varies among SARS-CoV-2 mutant strains. In this study, therefore, we investigated whether SARS-CoV-2 mutations increase infectivity to CNS cells, including microglia. Since it was essential to demonstrate the infectivity of the virus to CNS cells in vitro using human cells, we generated cortical neurons, astrocytes, and microglia from human induced pluripotent stem cells (hiPSCs). We added pseudotyped lentiviruses of SARS-CoV-2 to each type of cells, and then we examined their infectivity. We prepared three pseudotyped lentiviruses expressing the S protein of the original strain (the first SARS-CoV-2 discovered in the world), the Delta variant, and the Omicron variant on their envelopes and analyzed differences of their ability to infect CNS cells. We also generated brain organoids and investigated the infectivity of each virus. The viruses did not infect cortical neurons, astrocytes, or NS/PCs, but microglia were infected by the original, Delta, and Omicron pseudotyped viruses. In addition, DPP4 and CD147, potential core receptors of SARS-CoV-2, were highly expressed in the infected microglia, while DPP4 expression was deficient in cortical neurons, astrocytes, and NS/PCs. Our results suggest that DPP4, which is also a receptor for Middle East respiratory syndrome-coronavirus (MERS-CoV), may play an essential role in the CNS. Our study is applicable to the validation of the infectivity of viruses that cause various infectious diseases in CNS cells, which are difficult to sample from humans.
新冠病毒会导致神经损伤、全身炎症和免疫细胞异常。新冠病毒引起的神经损伤可能是由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的,该病毒会直接感染中枢神经系统(CNS)细胞并产生毒性作用。此外,SARS-CoV-2 不断发生突变,目前尚不清楚病毒突变时病毒对 CNS 细胞的感染力如何变化。很少有研究探讨中枢神经系统细胞(神经干细胞/祖细胞(NS/PCs)、神经元、星形胶质细胞和小胶质细胞)中 SARS-CoV-2 突变株的感染性是否存在差异。因此,在这项研究中,我们研究了 SARS-CoV-2 突变是否会增加对包括小胶质细胞在内的 CNS 细胞的感染力。由于在体外用人细胞证明病毒对 CNS 细胞的感染力至关重要,因此我们从人诱导多能干细胞(hiPSC)中生成皮质神经元、星形胶质细胞和小胶质细胞。我们将 SARS-CoV-2 的假型慢病毒添加到每种类型的细胞中,然后检查它们的感染力。我们制备了三种假型慢病毒,在其包膜上表达原始毒株(世界上首次发现的 SARS-CoV-2)、Delta 变体和奥密克戎变体的 S 蛋白,并分析了它们感染 CNS 细胞能力的差异。我们还生成了脑类器官,并研究了每种病毒的感染性。这些病毒不能感染皮质神经元、星形胶质细胞或 NS/PCs,但原始、Delta 和奥密克戎假型病毒可以感染小胶质细胞。此外,DPP4 和 CD147 是 SARS-CoV-2 的潜在核心受体,在感染的小胶质细胞中高度表达,而 DPP4 在皮质神经元、星形胶质细胞和 NS/PCs 中表达缺失。我们的结果表明,DPP4 也是中东呼吸综合征冠状病毒(MERS-CoV)的受体,可能在中枢神经系统中发挥重要作用。我们的研究适用于验证各种在 CNS 细胞中引起传染病的病毒的感染力,而从人体中取样这些病毒非常困难。